A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy

Hui Peng, Zizheng Dong, Jing Qi, Youyun Yang, Yang Liu, Zhaomin Li, Junkang Xu, Jian-Ting Zhang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Multidrug resistance (MDR) is a major problem in successful treatment of cancers. Human ABCG2, a member of the ATP-binding cassette transporter superfamily, plays a key role in MDR and an important role in protecting cancer stem cells. Knockout of ABCG2 had no apparent adverse effect on the mice. Thus, ABCG2 is an ideal target for development of chemo-sensitizing agents for better treatment of drug resistant cancers and helping eradicate cancer stem cells. Methods/Preliminary Findings: Using rational screening of representatives from a chemical compound library, we found a novel inhibitor of ABCG2, PZ-39 (N-(4-chlorophenyl)-2-[(6-{[4,6-di (4-morpholinyl)-1,3,5-triazin-2-yl]amino}-1,3-benzothiazol-2-yl) sulfanyl]acetamide), that has two modes of actions by inhibiting ABCG2 activity and by accelerating its lysosome-dependent degradation. PZ-39 has no effect on ABCB1 and ABCC1-mediated drug efflux, resistance, and their expression, indicating that it may be specific to ABCG2. Analyses of its analogue compounds showed that the pharmacophore of PZ-39 is benzothiazole linked to a triazine ring backbone. Conclusion/Significance: Unlike any previously known ABCG2 transporter inhibitors, PZ-39 has a novel two-mode action by inhibiting ABCG2 activity, an acute effect, and by accelerating lysosome-dependent degradation, a chronic effect. PZ-39 is potentially a valuable probe for structure-function studies of ABCG2 and a lead compound for developing therapeutics targeting ABCG2-mediated MDR in combinational cancer chemotherapy.

Original languageEnglish
Article numbere5676
JournalPLoS One
Volume4
Issue number5
DOIs
StatePublished - May 24 2009

Fingerprint

Chemotherapy
multiple drug resistance
Multiple Drug Resistance
Stem cells
drug therapy
Neoplastic Stem Cells
lysosomes
Lysosomes
Lead compounds
Drug Therapy
Degradation
Triazines
neoplasms
Chemical compounds
ATP-Binding Cassette Transporters
stem cells
mechanism of action
Pharmaceutical Preparations
Small Molecule Libraries
acetamides

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. / Peng, Hui; Dong, Zizheng; Qi, Jing; Yang, Youyun; Liu, Yang; Li, Zhaomin; Xu, Junkang; Zhang, Jian-Ting.

In: PLoS One, Vol. 4, No. 5, e5676, 24.05.2009.

Research output: Contribution to journalArticle

Peng, Hui ; Dong, Zizheng ; Qi, Jing ; Yang, Youyun ; Liu, Yang ; Li, Zhaomin ; Xu, Junkang ; Zhang, Jian-Ting. / A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. In: PLoS One. 2009 ; Vol. 4, No. 5.
@article{4247281b270a476eacf46c3d96275914,
title = "A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy",
abstract = "Background: Multidrug resistance (MDR) is a major problem in successful treatment of cancers. Human ABCG2, a member of the ATP-binding cassette transporter superfamily, plays a key role in MDR and an important role in protecting cancer stem cells. Knockout of ABCG2 had no apparent adverse effect on the mice. Thus, ABCG2 is an ideal target for development of chemo-sensitizing agents for better treatment of drug resistant cancers and helping eradicate cancer stem cells. Methods/Preliminary Findings: Using rational screening of representatives from a chemical compound library, we found a novel inhibitor of ABCG2, PZ-39 (N-(4-chlorophenyl)-2-[(6-{[4,6-di (4-morpholinyl)-1,3,5-triazin-2-yl]amino}-1,3-benzothiazol-2-yl) sulfanyl]acetamide), that has two modes of actions by inhibiting ABCG2 activity and by accelerating its lysosome-dependent degradation. PZ-39 has no effect on ABCB1 and ABCC1-mediated drug efflux, resistance, and their expression, indicating that it may be specific to ABCG2. Analyses of its analogue compounds showed that the pharmacophore of PZ-39 is benzothiazole linked to a triazine ring backbone. Conclusion/Significance: Unlike any previously known ABCG2 transporter inhibitors, PZ-39 has a novel two-mode action by inhibiting ABCG2 activity, an acute effect, and by accelerating lysosome-dependent degradation, a chronic effect. PZ-39 is potentially a valuable probe for structure-function studies of ABCG2 and a lead compound for developing therapeutics targeting ABCG2-mediated MDR in combinational cancer chemotherapy.",
author = "Hui Peng and Zizheng Dong and Jing Qi and Youyun Yang and Yang Liu and Zhaomin Li and Junkang Xu and Jian-Ting Zhang",
year = "2009",
month = "5",
day = "24",
doi = "10.1371/journal.pone.0005676",
language = "English",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy

AU - Peng, Hui

AU - Dong, Zizheng

AU - Qi, Jing

AU - Yang, Youyun

AU - Liu, Yang

AU - Li, Zhaomin

AU - Xu, Junkang

AU - Zhang, Jian-Ting

PY - 2009/5/24

Y1 - 2009/5/24

N2 - Background: Multidrug resistance (MDR) is a major problem in successful treatment of cancers. Human ABCG2, a member of the ATP-binding cassette transporter superfamily, plays a key role in MDR and an important role in protecting cancer stem cells. Knockout of ABCG2 had no apparent adverse effect on the mice. Thus, ABCG2 is an ideal target for development of chemo-sensitizing agents for better treatment of drug resistant cancers and helping eradicate cancer stem cells. Methods/Preliminary Findings: Using rational screening of representatives from a chemical compound library, we found a novel inhibitor of ABCG2, PZ-39 (N-(4-chlorophenyl)-2-[(6-{[4,6-di (4-morpholinyl)-1,3,5-triazin-2-yl]amino}-1,3-benzothiazol-2-yl) sulfanyl]acetamide), that has two modes of actions by inhibiting ABCG2 activity and by accelerating its lysosome-dependent degradation. PZ-39 has no effect on ABCB1 and ABCC1-mediated drug efflux, resistance, and their expression, indicating that it may be specific to ABCG2. Analyses of its analogue compounds showed that the pharmacophore of PZ-39 is benzothiazole linked to a triazine ring backbone. Conclusion/Significance: Unlike any previously known ABCG2 transporter inhibitors, PZ-39 has a novel two-mode action by inhibiting ABCG2 activity, an acute effect, and by accelerating lysosome-dependent degradation, a chronic effect. PZ-39 is potentially a valuable probe for structure-function studies of ABCG2 and a lead compound for developing therapeutics targeting ABCG2-mediated MDR in combinational cancer chemotherapy.

AB - Background: Multidrug resistance (MDR) is a major problem in successful treatment of cancers. Human ABCG2, a member of the ATP-binding cassette transporter superfamily, plays a key role in MDR and an important role in protecting cancer stem cells. Knockout of ABCG2 had no apparent adverse effect on the mice. Thus, ABCG2 is an ideal target for development of chemo-sensitizing agents for better treatment of drug resistant cancers and helping eradicate cancer stem cells. Methods/Preliminary Findings: Using rational screening of representatives from a chemical compound library, we found a novel inhibitor of ABCG2, PZ-39 (N-(4-chlorophenyl)-2-[(6-{[4,6-di (4-morpholinyl)-1,3,5-triazin-2-yl]amino}-1,3-benzothiazol-2-yl) sulfanyl]acetamide), that has two modes of actions by inhibiting ABCG2 activity and by accelerating its lysosome-dependent degradation. PZ-39 has no effect on ABCB1 and ABCC1-mediated drug efflux, resistance, and their expression, indicating that it may be specific to ABCG2. Analyses of its analogue compounds showed that the pharmacophore of PZ-39 is benzothiazole linked to a triazine ring backbone. Conclusion/Significance: Unlike any previously known ABCG2 transporter inhibitors, PZ-39 has a novel two-mode action by inhibiting ABCG2 activity, an acute effect, and by accelerating lysosome-dependent degradation, a chronic effect. PZ-39 is potentially a valuable probe for structure-function studies of ABCG2 and a lead compound for developing therapeutics targeting ABCG2-mediated MDR in combinational cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=66249099214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249099214&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0005676

DO - 10.1371/journal.pone.0005676

M3 - Article

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e5676

ER -